Abstract
Subcutaneous phycomycosis becomes a chronic, debilitating condition if left untreated. Treatment includes oral antifungal therapy, though oral potassium iodide has been used in resource-limited settings. Lugol's iodine has been an effective substitute, but little is known about its safety. We report a case of subcutaneous phycomycosis complicated by heart failure during treatment with Lugol's iodine. We review subcutaneous phycomycosis, iodine-mediated cardiotoxicity, as well as social determinants of health relevant to our case, suggesting that Lugol's iodine may only be an effective treatment with proper dosing and long-term monitoring.
| Original language | English |
|---|---|
| Pages (from-to) | 9-12 |
| Number of pages | 4 |
| Journal | Medical Mycology Case Reports |
| Volume | 38 |
| DOIs | |
| State | Published - Dec 2022 |
Keywords
- Fungal infection
- Heart failure
- Lugol's iodine
- Social determinants of health
- Subcutaneous phycomycosis
Fingerprint
Dive into the research topics of 'Adverse effects of Lugol's iodine: Heart failure in a patient with subcutaneous phycomycosis from a resource-limited setting'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver